Central effects of botulinum toxin type A

Evidence and supposition

Antonio Currà, Carlo Trompetto, Giovanni Abbruzzese, Alfredo Berardelli

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

No convincing evidence exists that botulinum toxin type A (BT-A) injected intramuscularly at therapeutic doses in humans acts directly on central nervous system (CNS) structures. Nevertheless, several studies, using various approaches, strongly suggest that BT-A affects the functional organization of the CNS indirectly through peripheral mechanisms. By acting at alpha as well as gamma motor endings, BT-A could alter spindle afferent inflow directed to spinal motoneurons or to the various cortical areas, thereby altering spinal as well as cortical mechanisms. Muscle afferent input is tightly coupled to motor cortical output, so that the afferents from a stretched muscle go to cortical areas where they can excite neurons capable of contracting the same muscle. The BT-A-induced reduction in spindle signals could, therefore, alter the balance between afferent input and motor output, thereby changing cortical excitability.

Original languageEnglish
JournalMovement Disorders
Volume19
Issue numberSUPPL. 8
DOIs
Publication statusPublished - 2004

Fingerprint

Type A Botulinum Toxins
Muscles
Central Nervous System
Motor Neurons
Neurons
Therapeutics

Keywords

  • Basic science
  • Botulinum toxin type A
  • Central nervous system
  • Cortical excitability
  • Intramuscular injection
  • Neurophysiology
  • Sensorimotor integration

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Central effects of botulinum toxin type A : Evidence and supposition. / Currà, Antonio; Trompetto, Carlo; Abbruzzese, Giovanni; Berardelli, Alfredo.

In: Movement Disorders, Vol. 19, No. SUPPL. 8, 2004.

Research output: Contribution to journalArticle

Currà, Antonio ; Trompetto, Carlo ; Abbruzzese, Giovanni ; Berardelli, Alfredo. / Central effects of botulinum toxin type A : Evidence and supposition. In: Movement Disorders. 2004 ; Vol. 19, No. SUPPL. 8.
@article{ac05c7d7eba847998dfb665ef254917d,
title = "Central effects of botulinum toxin type A: Evidence and supposition",
abstract = "No convincing evidence exists that botulinum toxin type A (BT-A) injected intramuscularly at therapeutic doses in humans acts directly on central nervous system (CNS) structures. Nevertheless, several studies, using various approaches, strongly suggest that BT-A affects the functional organization of the CNS indirectly through peripheral mechanisms. By acting at alpha as well as gamma motor endings, BT-A could alter spindle afferent inflow directed to spinal motoneurons or to the various cortical areas, thereby altering spinal as well as cortical mechanisms. Muscle afferent input is tightly coupled to motor cortical output, so that the afferents from a stretched muscle go to cortical areas where they can excite neurons capable of contracting the same muscle. The BT-A-induced reduction in spindle signals could, therefore, alter the balance between afferent input and motor output, thereby changing cortical excitability.",
keywords = "Basic science, Botulinum toxin type A, Central nervous system, Cortical excitability, Intramuscular injection, Neurophysiology, Sensorimotor integration",
author = "Antonio Curr{\`a} and Carlo Trompetto and Giovanni Abbruzzese and Alfredo Berardelli",
year = "2004",
doi = "10.1002/mds.20011",
language = "English",
volume = "19",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "SUPPL. 8",

}

TY - JOUR

T1 - Central effects of botulinum toxin type A

T2 - Evidence and supposition

AU - Currà, Antonio

AU - Trompetto, Carlo

AU - Abbruzzese, Giovanni

AU - Berardelli, Alfredo

PY - 2004

Y1 - 2004

N2 - No convincing evidence exists that botulinum toxin type A (BT-A) injected intramuscularly at therapeutic doses in humans acts directly on central nervous system (CNS) structures. Nevertheless, several studies, using various approaches, strongly suggest that BT-A affects the functional organization of the CNS indirectly through peripheral mechanisms. By acting at alpha as well as gamma motor endings, BT-A could alter spindle afferent inflow directed to spinal motoneurons or to the various cortical areas, thereby altering spinal as well as cortical mechanisms. Muscle afferent input is tightly coupled to motor cortical output, so that the afferents from a stretched muscle go to cortical areas where they can excite neurons capable of contracting the same muscle. The BT-A-induced reduction in spindle signals could, therefore, alter the balance between afferent input and motor output, thereby changing cortical excitability.

AB - No convincing evidence exists that botulinum toxin type A (BT-A) injected intramuscularly at therapeutic doses in humans acts directly on central nervous system (CNS) structures. Nevertheless, several studies, using various approaches, strongly suggest that BT-A affects the functional organization of the CNS indirectly through peripheral mechanisms. By acting at alpha as well as gamma motor endings, BT-A could alter spindle afferent inflow directed to spinal motoneurons or to the various cortical areas, thereby altering spinal as well as cortical mechanisms. Muscle afferent input is tightly coupled to motor cortical output, so that the afferents from a stretched muscle go to cortical areas where they can excite neurons capable of contracting the same muscle. The BT-A-induced reduction in spindle signals could, therefore, alter the balance between afferent input and motor output, thereby changing cortical excitability.

KW - Basic science

KW - Botulinum toxin type A

KW - Central nervous system

KW - Cortical excitability

KW - Intramuscular injection

KW - Neurophysiology

KW - Sensorimotor integration

UR - http://www.scopus.com/inward/record.url?scp=2942581451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942581451&partnerID=8YFLogxK

U2 - 10.1002/mds.20011

DO - 10.1002/mds.20011

M3 - Article

VL - 19

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - SUPPL. 8

ER -